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ABSTRACT: Decameric vanadate (V10) inhibits the actin-stimulated myosin ATPase activity, noncompeti-
tively with actin or with ATP upon interaction with a high-affinity binding site (Ki ) 0.27 ( 0.05 íM)
in myosin subfragment-1 (S1). The binding of V10 to S1 can be monitored from titration with V10 of the
fluorescence of S1 labeled at Cys-707 and Cys-697 with N-iodo-acetyl-N′-(5-sulfo-1-naphthyl)-
ethylenediamine (IAEDANS) or 5-(iodoacetamido) fluorescein, which showed the presence of only one
V10 binding site per monomer with a dissociation constant of 0.16-0.7 íM, indicating that S1 labeling
with these dyes produced only a small distortion of the V10 binding site. The large quenching of AEDANS-
labeled S1 fluorescence produced by V10 indicated that the V10 binding site is close to Cys-697 and 707.
Fluorescence studies demonstrated the following: (i) the binding of V10 to S1 is not competitive either
with actin or with ADPâV1 or ADPâAlF4; (ii) the affinity of V10 for the complex S1/ADPâV1 and S1/
ADPâAlF4 is 2- and 3-fold lower than for S1; and (iii) it is competitive with the S1 “back door” ligand
P1P5-diadenosine pentaphosphate. A local conformational change in S1 upon binding of V10 is supported
by (i) a decrease of the efficiency of fluorescence energy transfer between eosin-labeled F-actin and
fluorescein-labeled S1, and (ii) slower reassociation between S1 and F-actin after ATP hydrolysis. The
results are consistent with binding of V10 to the Walker A motif of ABC ATPases, which in S1 corresponds
to conserved regions of the P-loop which form part of the phosphate tube.
Although vanadium is one of the important transition
elements in biology (1), its physiological role is still a matter
of debate. At neutral pH and through the range of concentra-
tions most frequently employed in biochemical studies, the
predominant vanadate species are the monomer (H2VO4-),
dimer (H3V2O7-), and cyclic tetramer (V4O124-) (2, 3). Other
oligomers can also be formed; probably the most important
of them in biochemical terms is decameric vanadate
(V10O286-).1 Despite the low concentrations of vanadium
found in cells and tissues of higher organisms, vanadate
oligomers once administered or formed at special cell sites
may become inaccessible to hydrolysis and reduction due
to their stabilization upon binding to target ligands (4).
Indeed, recent work from our laboratory (5, 6) demonstrated
that an acute exposure to decameric vanadate species, but
not exposure to monomeric vanadate, induced oxidative
stress and lipid peroxidation, pointing out the importance of
taking into account different vanadate oligomers in the
evaluation of vanadium toxicity.
The ability of vanadate to inhibit enzymes is linked to its
physical and chemical properties as well as to its flexible
coordination chemistry. Vanadate monomer can act as a
ground state or transition state analogue of inorganic
phosphate, which has made this ion a valuable tool for
studying enzyme-catalyzed phosphotransfer and phospho-
hydrolase reactions (7). This is particular relevant for myosin
(M), the major ATPase of muscle, that is strongly inhibited
by vanadate. The head segment of myosin, called subfrag-
ment 1 (S1), contains the binding sites for ATP and actin,
and is responsible for the ATPase activity during the process
of muscle contraction (8). The binding of ATP reduces the
affinity of myosin for actin, and the subsequent hydrolysis
of ATP results in a ternary complex between myosin, ADP.
and inorganic phosphate (Pi). The rate-limiting step of the
ATP hydrolysis is the release of Pi from myosin, which is
accelerated by the rebinding of actin (9). Vanadate inhibits
myosin ATPase activity by forming, in the absence of actin,
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a very stable complex with MgADP that mimics either the
transition state of hydrolysis or the ADPâPi intermediate state
(10). In the presence of actin, the rate of vanadate release
increases by 105 compared to that of MâADPâV1 alone (5 
10-6 s-1) (11). Although the actin-stimulated myosin ATPase
activity has been described to be about 90% inhibited by
ADPâV1 (12), it was suggested that this inhibition could be
due in part to the presence of polymeric vanadate ions,
because high vanadate concentrations (> 900 íM) are needed
(13). In fact, it has been suggested that tetrameric vanadate
(V4) interacts with myosin, being responsible for the vana-
date-induced photolytic cleavage of myosin subfragment 1
(14, 15). More recently, Yount et al. (16) have proposed that
in the presence of excess Vi (a mixture of monomeric and
polymeric vanadate ions), Vi could enter the active site via
the “back door” to form the more stable MgADPâViâmyosin
complex to relax the fibers.
Besides V4, there are indications that also vanadate
decamer (V10) may interact with myosin (17), although little
is known about its putative binding sites and functional
relevance. More recently, fluorescent quenching studies have
provided evidence for decavanadate high-affinity binding
sites in myosin (18). We now show that the actin-stimulated
myosin ATPase activity is indeed strongly inhibited by V10
and that this inhibition is due to the binding of this covalently
closed polyanionic species of ellipsoidal-like shape (4, 19)
to a specific high-affinity site in the myosin headgroup.
In a previous study using the intrinsic fluorescence of
myosin to monitor decavanadate-myosin interaction (18),
it was suggested that myosin has binding site(s) for deca-
vanadate with an overall dissociation constant in the micro-
molar range at high ionic strength (0.3 M KCl). We have
named them “high affinity” site(s) because in the titration
of the intrinsic fluorescence of myosin with up to 1 mM
decavanadate showed a biphasic pattern with further quench-
ing in the sub-millimolar range (Tiago, T., Aureliano, M.,
and Gutie´rrez-Merino, C., unpublished results). However, the
limited solubility of overall myosin molecules precluded
extending this study to lower ionic strength. In addition,
because of the scattered distribution of Trp in the myosin
3D structure, and the occurrence of photon energy migration
between them in the protein structure, the location of the
putative interactions site(s) between decavanadate and myo-
sin remained to be clarified.
Because myosin subfragment 1 (S1) labeled with fluores-
cent dyes at Cys-707 and Cys-697 have been widely used
to monitor interactions of different modulators of the actin-
stimulated myosin ATPase activity (see for example refs 20-
23), we explored whether these labeled S1 can be used to
gain a deeper knowledge of decavanadate-myosin interac-
tions. These cysteines, termed SH1, and SH2, are the most
commonly modified residues in myosin, being highly reactive
with a variety of sulfhydryl directed compounds (24).
Although they do not appear to be directly involved in ATP
hydrolysis, they are located at a key position in the path of
intersite signal transmission (21, 24, 25), which makes them
suitable reporter groups to monitor the functional events on
the myosin head. In the present study, we report kinetic and
fluorimetric studies on the effects of decavanadate on the
actin-stimulated S1 ATPase activity and fluorescence of S1
labeled with IAEDANS and IAF at Cys-707 and Cys-697.
In addition, the possibility of modulation of the F-actin/S1
complex by decavanadate has been studied by light scattering
and FRET measurements as well as the effect of decavana-
date on actin polymerization/depolymerization by light
scattering measurements and fluorescence depolarization of
eosin-labeled actin.
MATERIALS AND METHODS
Reagents. Chemicals used to prepare buffers were reagent
grade. Ammonium metavanadate was purchased from Riedel-
de-Ha¨en (Germany). DTT, FDNB, ATP, ADP, AP5A,
NADH, phosphoenolpyruvate, trypsin, and R-chymotrypsin
were supplied by Sigma Chemical Co (St. Louis, MO). Py-
ruvate kinase and lactate dehydrogenase were purchased from
Roche Molecular Biochemicals (Mannheim, Germany).
N-Iodo-acetyl-N′-(5-sulfo-1-naphthyl)ethylenediamine (IAE-
DANS), 5-(iodoacetamido) fluorescein (IAF), eosin-5-io-
doacetamide, and mant-AMPPNP were supplied by Molec-
ular Probes (Eugene, OR).
Proteins. Myosin was prepared from leg and dorsal white
rabbit skeletal muscle, as previously described by Pires et
al. (26). Subfragment 1 was prepared by chymotryptic
digestion of myosin according to Margossian and Lowey
(27). F-Actin was prepared from acetone powder of rabbit
skeletal muscle as described by Pardee and Spudich (28).
Protein concentrations were determined spectrophotometri-
cally by using extinction coefficients of E280
1% ) 5.7 cm-1 for
myosin, E280
1% ) 7.5 cm-1 for S1 and E290
1% ) 11.5 cm-1 for
actin. The molecular masses used were 500, 115, and 42
kDa for myosin, S1, and actin, respectively.
Vanadate Solutions. Stock solutions of decavanadate were
prepared in a manner that maximized the proportion of
vanadate that was present as the decamer, by adjusting the
pH of the metavanadate stock solutions (50 mM NH4VO3,
pH 6.0-7.0) to pH between 3 and 5 (29). It has been shown
by NMR spectroscopy that a decavanadate stock solution
contains exclusively decameric vanadate species (30). On
the other hand, only for metavanadate concentrations lower
than 200 íM, orthovanadate species are exclusively present
(30, 31). In contrast to the labile oxovanadates, which
interconvert on the time scale of milliseconds to seconds,
decameric vanadate has a very slow dissociation kinetics
upon dilution (32). The kinetics of dissociation of decameric
species in the experimental conditions used in this study (25
°C, 20 mM Hepes, pH 7.0) assessed by measurements of
the absorption at 400 nm (an absorption band that is
characteristic of decameric vanadate) is confirmed as a first-
order kinetic process with a half-life of 158 min (measured
with 50 íM total vanadium concentration). Therefore, this
oxoanion remains stable during the period used in the
experiments. Metavanadate or decavanadate solutions were
added to the assays from the concentrated form or from a
10-fold dilution of the stock solutions. The pH changes of
the assay medium during titration with decavanadate or
metavanadate solutions were always less than 0.05 pH units.
Kinetic Studies. Steady-state assays of the Mg2+-ATPase
and the actin-activated S1 ATPase were measured spectro-
photometrically at 25 °C using the coupled enzyme pyruvate
kinase/lactate dehydrogenase assay (33) with the following
reaction mixture: 20 mM Hepes (pH 7.0), 2.5 mM MgCl2,
0.1-2 mM ATP, 0.42 mM phosphoenolpyruvate, 0.375 mM
NADH, 18 IU lactate dehydrogenase, and 18 IU pyruvate
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kinase. The detection system was not affected by the range
of decavanadate concentrations used in this study (0-100
íM total vanadate concentration), as was confirmed by a
rapid decrease in absorbance at 340 nm upon addition of 40
íM ADP after the assay.
CoValent Modification of Proteins. Myosin S1 (5-6 mg/
mL) was labeled at SH1 (Cys-707) with IAEDANS or IAF
as previously described (20, 24). Prior to labeling, S1 was
dialyzed against 60 mM KCl, 25 mM Hepes, pH 7.5. The
dialyzed sample was then incubated on ice for 1 h in the
dark with a 20-fold molar excess of IAEDANS (dissolved
in the same buffer) or with a 5-fold molar excess of IAF
(dissolved in buffer at pH 9.0). The reaction was stopped
by adding an excess of DTT, and unreacted probe was
subsequently removed on a PD-10 column (Pharmacia).
These labeled S1 samples are named as S1(AEDANS, SH2)
and S1(AF, SH2), respectively. Myosin S1 (5-6 mg/mL)
was also labeled at SH2 (Cys-697) with IAEDANS or IAF
as previously described (20, 24). To avoid the labeling of
Cys-707, this residue was reversibly blocked by reacting S1
with a 2-fold molar excess of FDNB at 4 °C for 30 min in
the presence of 1 mM MgCl2, 1 mM ADP, 60 mM KCl,
and 25 mM Hepes, pH 8.0. FDNB-protected S1 was
subsequently incubated at 4 °C for 1 h in the dark in the
presence of 5 mM MgCl2 and 5 mM ADP with a 8-fold
molar excess of IAEDANS or with a 2-fold molar excess of
IAF. The reaction was stopped by the addition of 10 mM
DTT and the protective dinitrobenzene group was removed
from SH1 by incubation with 10 mM DTT at 4 °C overnight.
The excess of the probe and DTT were removed on a PD-
10 column (Pharmacia). These labeled S1 samples are named
as S1(SH1, AEDANS) and S1(SH1, AF), respectively.
F-actin was labeled at Cys-374 with a 5-fold molar excess
of eosin on ice for 2 h, followed by the addition of an excess
of DTT to stop the reaction. The labeled F-actin was
extensively dialyzed against a buffer containing 0.2 mM
ATP, 2 mM MgCl2, 50 mM KCl, and 2 mM Tris-HCl, pH
8.0 to remove the unreacted probe. The labeled F-actin was
used within several days and immediately before fluorescence
measurements was dialyzed against 2 mM MgCl2, 50 mM
KCl, and 2 mM Tris-HCl, pH 8.0 to remove free nucleotide.
The extent of labeling of myosin S1 and F-actin by the probes
was estimated spectrophotometrically using the following
extinction coefficients: E337
1% ) 6100 M-1 cm-1 for IAE-
DANS, E495
1% ) 80 000 M-1 cm-1 for IAF, and E519
1% )
100 000 M-1 cm-1 for eosin. For this purpose, concentrations
of labeled S1 were measured by the Bradford protein assay
(34) using bovine serum albumin as a standard. The degrees
of labeling of SH1 of myosin S1 were in the range of 0.7-1
for both labels, while the labeling of SH2 was about 0.9 for
IAEDANS and 0.5 for IAF. Fluorescence polarization (P)
of labeled proteins was routinely measured for two major
reasons: (i) to test for the possibility of unreacted dye
contamination, whose fluorescence is largely depolarized (P
< 0.005) and (ii) to calculate the anisotropy of the attached
dye, which is needed for FRET analysis. The specificity of
the labeling on S1 was verified by measurements of both
Ca2+-ATPase and K+/EDTA-ATPase activities and by a
12.5% SDS-polyacrylamide gel electrophoresis of partially
trypsin-digested labeled S1 in which the fluorescence frag-
ments were located on unstained gels under UV illumination
(20). The ATPase activities (Ca2+- and K+/EDTA-ATPase)
of S1 were measured by determination of inorganic phos-
phate release (35). The assays were carried out at room
temperature in 50 mM Tris-HCl (pH 7.9), 2.5 mM ATP,
and either 0.23 M KCl and 2.5 mM CaCl2 for Ca2+-ATPase
or 0.6 M KCl and 1 mM EDTA for K+/EDTA-ATPase
activities, using 0.1 mg/mL of protein. In agreement with
previous reports (20, 36), the covalent modification of SH1
with IAEDANS displayed an increase in the Ca2+-ATPase
activity by a factor of 2.4-3 and an inhibition of the K+/
EDTA-ATPase activity of 90%. When SH1 was modified
by IAF, the Ca2+-ATPase activity was enhanced by a factor
of 1.4-1.6 and the K+/EDTA-ATPase activity was inhibited
by 45%. S1 labeled at SH2 was inhibited in both the Ca2+-
ATPase and K+/EDTA-ATPase activities, by at least 30 and
50%, respectively. The fluorescence fragments of the partially
digested labeled S1 were located on unstained SDS-
polyacrylamide gels under UV illumination. The gels showed
a single fluorescent band in the 20-kDa peptide segment in
which SH1 and SH2 are found.
Preparation of Stable S1 Transition State Complexes. The
complexes S1âADPâVO43- and S1âADPâAlF4- were pre-
pared with the labeled protein S1(AEDANS, SH2) and S1-
(AF, SH2) as previously described (22). Briefly, labeled S1
in 60 mM KCl, 25 mM Hepes, pH 7.9 was incubated at 25
°C for 5 min with 1 mM MgCl2, 0.2 mM ADP, and, for
AlF4- with 5 mM NaF. Then, metavanadate solution (for
VO43-) or AlCl3 (for AlF4-) was added to a final concentra-
tion of 0.2 mM, and the incubation was continued for 90
min at 25 °C. To remove excess of nucleotide analogues,
the samples were passed through a PD-10 column (Pharma-
cia).
Fluorescence Measurements. Steady-state fluorescence
measurements were performed in a continuously stirred
cuvette with the following spectrofluorimeters: Hitachi-
Perkin-Elmer (model 650-40) and SLM-4800C, with cali-
brated polarizers for polarization measurements. All experi-
ments were performed at 25 °C in a medium containing 20
mM Hepes, pH 7.0 and 2.5 mM MgCl2. S1-AEDANS and
S1-AF emissions were monitored at 470 and 520 nm with
excitation at 336 and 490 nm, respectively. The binding of
vanadates to S1 was monitored by titration of modified S1
(0.45 íM) with metavanadate or decavanadate solutions
ranging from 0 to 50 íM total vanadium concentration. Inner
filter effects, due to the absorbance at 336 and 470 nm of
metavanadate and decavanadate, were corrected using the
following equation: Fcorr ) CFobs, where Fcorr and Fobs are
the values of the corrected and observed fluorescence,
respectively, and C ) antilog [(A336 + A470)/2] (37), with
the following extinction coefficients (determined under our
experimental conditions from stock metavanadate and de-
cavanadate solutions): 0.4 mM-1 cm-1 for metavanadate at
336 nm, and 1.12 and 0.09 mM-1 cm-1 for decavanadate at
336 and 470 nm, respectively. Eosin-F-actin fluorescence
was measured with excitation and emission wavelengths set
at 475 and 520 nm, respectively.
Polarization of fluorescence was calculated by using the
expression (38): P(ì) ) [(I| - G(ì)I⊥)/(I| + G(ì)I⊥)], where
I| and I⊥ are the fluorescence intensities measured with
parallel and perpendicularly oriented polarizers, respectively,
and G(ì) is the correction factor for the polarization
characteristics of the emission monochromator. For each
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excitation/emission setup the value of G(ì) was averaged
from more than 10 measurements, and for the polarization
measurements done in this work it was 1.085 ( 0.005
(IAEDANS-S1) and 1.140 ( 0.005 (IAF-S1). The steady-
state anisotropy of fluorescence, rs, has been calculated from
the measured polarization (P) by using the equation (38):
rs ) 2P/(3 - P).
Dissociation constants were obtained using the program
Origin 5.0, from the slopes of the linear least-squares fit of
the fluorescence titration data to the Scatchard equation,
taking the fractional change of fluorescence (or anisotropy
for mant-AMPPNP titration) as the fraction of saturated
binding sites (â). Thus, bound ligand concentration: [bound]
) nâ[S1], where n ) number of binding sites/S1 monomer;
and free ligand concentration: [free] ) [total ligand] -
[bound].
Analysis of Fluorescence Energy Transfer (FRET). The
calculations of distances from steady-state fluorescence
energy transfer measurements have been done using the basic
equation for one donor/acceptor pair (39). The distance R0
for the pairs IAF-S1/eosin-F-actin and IAEDANS-S1/V10
has been calculated as in Gutie´rrez-Merino et al. (40), with
the equation (41):
using a value for 2 ) 2/3 (which corresponds to a random
orientation between donor and acceptor), with a refractive
index Ł ) 1.33, i.e., equal to that of a dilute aqueous solution,
and with the donor quantum yield measured for IAF-S1
(QD ) 0.35 ( 0.05) and IAEDANS-S1 (QD ) 0.18 ( 0.03)
using 1 mM quinine sulfate in 1 N sulfuric acid at 25 °C as
a reference standard, as in Centeno and Gutie´rrez-Merino
(42). The overlap integral values were calculated from the
absorption and corrected emission spectra of the acceptor
and donor, respectively, as in previous papers (40, 42).
Light-Scattering Measurements. Light scattering intensity
was monitored at 90° with respect to the incident light at 25
°C, using a Perkin-Elmer 650-40 spectrofluorimeter. Both
monochromators were set at 400 nm for the polymerization
measurements of actin or at 500 nm (to avoid inner filter
effects by decavanadate) for the experiments with S1 and
F-actin/S1 complex.
RESULTS
Inhibition of the Actin Stimulated S1 ATPase ActiVity by
V10. Addition of decavanadate produced inhibition of the
actin-stimulated myosin S1 ATPase activity (Table 1). The
inhibition is attained in less than 15 s, as shown by the
linearity of the kinetic traces of the ATPase activity after
manual mixing since the starting point and for a period
lasting more than 10 min. As metavanadate (up to 150 íM
of total vanadium concentration) produced less than 20%
inhibition of this activity, these results also showed that
decavanadate remains stable in the assay medium for, at least,
30 min, in good agreement with our measurements of the
stability of decavanadate determined from the absorbance
at 400 nm of decavanadate solutions in 20 mM Hepes, pH
7.0 (see Materials and Methods).
Increasing the F-actin concentration from 0.5 to 4 íM,
while keeping the S1 concentration fixed to 0.45 íM in the
ATPase assay, did not increase the concentration of V10
required to produce 50% inhibition (IC50) of actin-stimulated
S1-ATPase activity, but at most slightly decreased it from
0.75 ( 0.07 to 0.55 ( 0.05 íM of V10 when F-actin increased
from 0.5 to 4 íM (Table 1). Therefore, we can exclude that
this inhibition is the result of a direct competition between
F-actin and decavanadate for binding to S1. Consistently,
V10 was also found to inhibit the S1-ATPase activity in the
absence of F-actin, but with an IC50 value of 12.5 íM, i.e.,
approximately 20-fold higher than that obtained in the
presence of 2-4 íM F-actin. These results suggested that
the binding site of V10 which accounted for inhibition of the
S1-ATPase activity is likely to be located near the functional
protein domains altered upon F-actin binding to S1, e.g., the
catalytic or the energy transduction domain connecting
catalytic and F-actin binding sites (8).
To question the possibility that the inhibition of the actin-
stimulated S1-ATPase activity by V10 can be due to competi-
tion with the substrate ATP, we have studied the inhibition
of actin-stimulated S1-ATPase at different ATP concentra-
tions. The obtained results are presented in Figure 1 in the
form of Hanes plots, and showed that the inhibition by V10
is noncompetitive with ATP, yielding an inhibition constant
(Ki) of 0.27 ( 0.05 íM V10 (2.7 ( 0.5 íM total vanadium
concentration). Owing to the relevance of this point, we have
studied the effect of V10 on the binding of ATP to S1, which
has been monitored from the increase of anisotropy of a
mant-fluorescent ATP analogue upon binding to S1, as in
ref 43. To avoid ATP hydrolysis during these binding studies,
we have used the non-hydrolysable mant-AMPPNP analogue
instead of mant-ATP. The results are presented in the Figure
2, and analyzed with Scatchard plots using the fractional
increase of fluorescence anisotropy [(r - rmin)/(rmax - rmin)]
as the molar fraction of bound mant-AMPPNP (inset of
Figure 2). From the slopes of the linear least-squares fit of
the Scatchard plots of these data, the following values for
the dissociation constant of mant-AMPPNP were obtained
(R > 0.96 in all the cases): 0.23 ( 0.02 íM (in the absence
of V10), 0.26 ( 0.02 and 0.23 ( 0.02 íM (in the presence
of 5 and 10 íM of V10). Thus, V10 binding to S1 is
noncompetitive with ATP binding.
These results showed that the inhibition of actin-stimulated
S1-ATPase activity by V10 is the result of slowing down the
catalytic cycle by binding at a regulatory site different from
the nucleotide site of the catalytic center. Because the IC50
value for inhibition by decavanadate of the actin-stimulated
S1-ATPase corresponds to a V10/S1 molar ratio of 1.0-1.5/
1, we studied the dependence of the IC50 value with S1
R0 ) 9.76  103 (JŁ-42QD)1/6 (Å) (1)
Table 1: Effect of Actin Concentration on V10 Inhibition Constants
of Myosin S1 ATPase Activitya
[actin] (íM) IC50 (íM)
0 12.5 ( 0.25
0.5 0.75 ( 0.06
1.0 0.60 ( 0.06
2.0 0.58 ( 0.06
4.0 0.55 ( 0.05
a The assays were performed at 25 °C using a coupled enzyme system
(as described in Materials and Methods) with 0.45 íM S1 in 20 mM
Hepes (pH 7.0), 2 mM ATP, and 2.5 mM MgCl2. Decavanadate final
concentrations ranging from 0 to 100 íM (total vanadium concentration)
were added to the medium, from a decavanadate stock solution of 5 or
50 mM. IC50 values are the average of the results obtained with at
least three different S1 and F-actin preparations.
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concentration, maintaining the ratio of actin/S1 concentra-
tions constant. The IC50 was linearly dependent upon the S1
concentration yielding a slope of 1.06 ( 0.12 íM V10/íM
S1 (Figure 1C), thus showing that it is caused by the binding
of V10 species to one inhibitory high-affinity site per molecule
of myosin S1.
Location of the Binding Site of V10 that Produced Inhibi-
tion of the Actin Stimulated S1-ATPase ActiVity. Recently
(18), we have shown the presence of a high-affinity binding
site for V10 in myosin from intrinsic fluorescence quenching
studies. Nevertheless, the possibility that the inhibition of
the actin-stimulated myosin ATPase activity could be due
to V10 binding to F-actin instead to myosin or to impairment
of the interaction between myosin and F-actin cannot be
excluded solely on these grounds.
However, the possibility of a direct interaction of V10 with
F-actin can be discarded because decavanadate (up to 200
íM total vanadium): (i) had no effect on the fluorescence
of F-actin-eosin nor on the intrinsic fluorescence of F-actin;
(ii) had no effect on the light scattering of F-actin (thus
implying that it does not promote F-actin dissociation); and
(iii) had no effect on the rate of F-actin polimerization
(measured using the light scattering approach, as in Cooper
and Pollard (44) (results not shown).
Therefore, we decided to gain a deeper knowledge of the
interaction of decameric vanadate with its high-affinity
binding site in myosin S1. To this end, we have labeled Cys-
707 of S1 with IAEDANS and with IAF following estab-
lished protocols as indicated in Materials and Methods. V10
was found to inhibit the actin-stimulated S1-ATPase activity
of labeled S1, but with IC50 values higher than that obtained
for control S1 (0.7 ( 0.1 íM V10), namely, 1.6 ( 0.2 íM
for S1(AF, SH2) and 8.9 ( 1.3 íM for S1(AEDANS, SH2).
These results suggested functional interaction between SH1
and V10 binding sites. The results of the titration of the
fluorescence of labeled S1(AEDANS, SH2) and of S1(AF,
SH2) with decavanadate are shown in Figure 3A. The
relatively large magnitude of the fluorescence changes found
at saturation with V10 (Figure 3A) suggested a close
proximity between the binding site for V10 and Cys-707.
Control experiments carried out with IAEDANS-Cys and
IAF-Cys showed that V10 did not affect directly the fluo-
FIGURE 1: Inhibition by decavanadate of actin-stimulated S1 Mg2+-
ATPase activity. The assays were performed at 25 °C, in 20 mM
Hepes, 25 mM KCl and 2.5 mM MgCl2 (pH 7.0). (A) Hanes plot
of [ATP]/V versus vanadate concentrations up to 100 íM in total
vanadium added (i.e., up to 10 íM V10) for ATP concentrations of
0.1 mM (squares), 0.5 mM (circles), 1 mM (up triangles), and 2
mM (down triangles). The studies were carried out with 0.45 íM
S1 and 2 íM actin. (B) The plot was made with the slopes obtained
from the Hanes plot versus [vanadate] to calculate the Ki value
from the intercept of the ordinate. (C) Dependence of the IC50
(concentration of decavanadate producing 50% inhibition of actin-
stimulated S1 Mg2+-ATPase activity) with 2 mM ATP and S1
concentration (0.11-0.9 íM), maintaining a constant actin/S1
concentration ratio of 4.4.
FIGURE 2: Fluorescence anisotropy titration of 0.1 íM mant-
AMPPNP with myosin-S1 concentrations ranging from 0.05 to 3
íM, in the absence (squares) and presence of 5 íM (circles) and
10 íM (triangles) V10 concentrations. Dissociation constants were
determined from the slopes of the linear least-squares fit of the
Scatchard plots (inset plot). Fluorescence measurements (excitation
wavelength 357 nm; emission wavelength 447 nm) were carried
out at 25 °C, in 20 mM Hepes, 25 mM KCl and 2.5 mM MgCl2
(pH 7.0).
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rescence of these dyes (less than 2% effect up to 200 íM
V10). These results showed that V10 produced partial quench-
ing of the fluorescence of S1(AEDANS, SH2) and increase
of the fluorescence of S1(AF, SH2) with saturation charac-
teristics of the ligand binding to a protein. Titration with
V10 at different concentrations of labeled S1 (results not
shown) showed that the concentration of V10 producing 50%
of the maximum fluorescence change can be fit to a straight
line with a slope of 1.0 ( 0.1 íM V10 species/íM S1, thus
confirming that fluorescence quenching is the result of
binding of V10 to a single site per mole of S1. Given that in
previous NMR studies (29) it was shown that upon dilution
to the reaction medium, the decavanadate solutions can
contain approximately 10% of orthovanadate, to ascertain
whether the orthovanadate added with decavanadate solution
can account for the effects on the fluorescence shown in
Figure 3A, we have carried out titration with a metavanadate
solution (containing only orthovanadate) of the fluorescence
of S1(AEDANS, SH2) and of S1(AF, SH2) (Figure 3C). The
results showed that the contaminant orthovanadate cannot
account for the fluorescence changes produced by titration
with decavanadate solutions. Because the fractional fluores-
cence change (¢F/¢Fmax) can be taken as the fraction of
occupied V10 binding sites, bound and free V10 were
calculated from the results of the titration with V10 of the
fluorescence of S1(AEDANS, SH2) with one binding site
per molecule of S1 (see above). From the slopes of Scatchard
plots of the data (see for example inset of Figure 3A), we
have obtained the following dissociation constants (Kd) for
V10: 0.26 ( 0.02 íM for S1(AEDANS, SH2) and 0.16 (
0.05 íM for S1(AF, SH2). These values for the dissociation
constant of V10 from S1 are identical, for S1(AEDANS, SH2),
or close, for S1(AF, SH2), to the Ki value of inhibition of
actin-stimulated unlabeled S1-ATPase activity obtained from
Hanes plots, 0.27 ( 0.05 íM (see above). This indicated
that binding of V10 is not significantly altered by AF or
AEDANS labeling of Cys-707, and suggested that the
observed increase of IC50 for V10 in S1(AEDANS, SH2) or
S1(AF, SH2) is related to the alteration of the catalytic cycle
produced by S1 labeling.
To further assess this point, we labeled S1 at the
“so-called” SH2 group (Cys-697), which is also located in
this protein domain (45), with IAEDANS and IAF (as
indicated in Materials and Methods) and carried out the
titration of S1(SH1, AEDANS) and S1(SH1, AF) with V10.
Cys-697 labeling with IAEDANS or with IAF was found to
have no effect on the IC50 value for V10 inhibition of actin-
stimulated S1 ATPase activity. The results are presented in
the Figure 3B, and the Scatchard plot of the data yielded
the following Kd values for V10: 0.40 ( 0.02 and 0.70 (
0.04 íM for S1(SH1, AEDANS) and S1(SH1, AF), i.e.,
between 1.5 and 3-fold higher than the Ki obtained from
Hanes plots and close to those obtained from the data shown
in Figure 3A. Therefore, labeling at the SH2 group with
AEDANS or AF decreased the free energy of V10 binding
to the inhibitory site [¢G ) RT ln(Kd1/Kd2)] by nearly 0.6
kcal/mol, indicating only a small distortion of the V10 binding
site. Again, the data shown in Figure 3C ruled out any
significant contribution of orthovanadate to the quenching
of the fluorescence of S1(SH1, AEDANS) and S1(SH1, AF)
produced by titration with V10.
The affinity of V10 for this site in S1 is strongly dependent
upon ionic strength, showing the relevance of electrostatic
interactions for decameric vanadate binding to S1, and that
FIGURE 3: Dependence of the fluorescence of labeled S1 upon
decavanadate (A and B) and metavanadate (C) concentration.
Y-axis: fluorescence relative to the fluorescence in the absence of
decavanadate or metavanadate. Small volumes of vanadate solutions
were successively added to 0.45 íM of labeled S1 from 5 or 50
mM decavanadate or metavanadate stock solutions. In panels A
(S1 labeled at SH1 - Cys 707) and B (S1 labeled at SH2 - Cys
697), squares and circles represent the labeling with IAEDANS
and IAF, respectively. In panel C, squares represent the labeling
with IAEDANS at SH1 residue and triangles the labeling with
IAEDANS at SH2 and IAF at SH1 and SH2 residues. Dissociation
constants were determined from the slopes of the linear least-squares
fit of the Scatchard plots (see for example inset plot of panel A).
All measurements were made at 25 °C in a medium containing 20
mM Hepes (pH 7.0), 25 mM KCl, 2.5 mM MgCl2. IAEDANS and
IAF fluorescence were measured with emission wavelengths of 470
and 517 nm, and with excitation wavelengths of 336 and 490 nm,
respectively.
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at a close to physiological ionic strength (0.2 M KCl) the
IC50 for inhibition of the actin-stimulated myosin ATPase
activity by V10 is below 2.5 íM (results not shown).
Effect of Different Myosin ATPase Modulators on the
Interaction of V10 with S1. As the results shown above
indicated that the inhibition of actin-stimulated S1-ATPase
activity by V10 is noncompetitive either with actin or with
ATP, we considered next that the affinity for V10 of different
conformational states of S1, which become populated during
the catalytic cycle (46-48), can be significantly different.
To this end, ADPâV1 and ADPâAlF4 complexes were
prepared with labeled S1 to mimic the intermediate activated
S1**âADPâPi state, as described elsewhere (22, 23). The
results of titration with V10 of the fluorescence of S1-
(AEDANS, SH2) and of S1(AF, SH2) pointed out that (i)
although ADPâV1 and ADPâAlF4 produced partial quenching
of the fluorescence of S1(AEDANS, SH2) (as previously
reported in ref 23), V10 binding produced an additional
quenching of this fluorescence, which at saturation is the
same as that found in absence of ADPâV1 or ADPâAlF4; (ii)
at saturation of V10 the increase of S1(AF, SH2) fluorescence
in the presence of ADPâV1 or ADPâAlF4 is about 20% higher
than that obtained in absence of the nucleotide complex
ADPâV1 or ADPâAlF4 (which produced approximately 20%
quenching of the fluorescence of S1(AF, SH2); and (iii) in
the presence of ADPâV1 or ADPâAlF4 the dissociation
constant of V10 from S1 is only weakly increased (Table 2).
In addition, the results obtained with S1(AEDANS, SH2)
demonstrated that V10 species do not bind to the catalytic
site, as the extent of quenching produced at saturation with
V10 is not affected by the presence of ADPâV1 or ADPâAlF4,
and for S1(AF, SH2) the effect of decavanadate (increase of
fluorescence) is opposite to the effect of ADPâV1 or ADPâ
AlF4 (quenching).
AP5A has been shown to bind to S1 and to actomyosin in
myofibrils and skinned fibers in a bimodal way that extends
from the nucleotide binding site at the catalytic crevice
through the “so-called” phosphate tube and to the 50-K cleft
leading to the back door of the catalytic center (49). Because,
the helix connecting Cys-707 and Cys-697 is at the bottom
of the 50-K cleft leading to the back door of the catalytic
center (50), and the results shown above suggested a close
proximity between the binding site for V10 and labels
covalently bound to these cysteines, we decided to question
whether binding of V10 compete with AP5A, through binding
to a site close to the back door of the catalytic center.
Titration of the fluorescence of S1(AF, SH2) with AP5A
allows to monitor the binding of AP5A (Figure 4A), and the
slopes of the Scatchard plots of these data yielded values
for the Kd of the AP5A/S1 complex of 37 ( 2 íM AP5A in
the absence of V10 and 133 ( 5 íM AP5A in the presence
of 5 íM V10, i.e., 50 íM total vanadium (Figure 4A). The
Kd of the V10âS1 complex obtained from the slopes of the
Scatchard plots of the data shown in the Figure 4B increased
from 0.16 ( 0.04 íM V10 in absence of AP5A to 5.8 ( 0.2
íM V10 in the presence of 200 íM AP5A. Thus, V10 and
AP5A compete for binding to S1.
Effect of V10 on the S1/F-Actin Association. The effect of
V10 on the light scattering of the acto-S1 complex solution
is shown in the Figure 5. In the absence of ATP, there is
only a small change on the light scattering of the complex
(amounting to less than 10%) at V10 concentrations that
produced more than 80% inhibition of the actin-stimulated
S1-ATPase activity, with no indications of dissociation of
the acto-S1 complex (the effect of addition of ATP is
included to illustrate this point). However, V10 but not
orthovanadate produced a large increase in the time needed
to reassociate S1 and actin after consumption of added ATP
(compare Figure 5, panels B and C), and this increase is
Table 2: Effect of Different Myosin Modulators on the Dissociation




none 0.26 ( 0.03 0.16 ( 0.04
ADP-V1 0.45 ( 0.05 0.25 ( 0.03
ADP-AlF4 0.62 ( 0.07 0.46 ( 0.05
a AEDANS and AF fluorescence were measured at 25 °C with
emission wavelengths of 470 and 517 nm, and excitation wavelengths
of 336 and 490 nm, respectively, in 20 mM Hepes, 2.5 mM MgCl2,
and 25 mM KCl (pH 7.0). Decavanadate final concentrations ranging
from 0 to 100 mM (total vanadium concentration) were added to the
medium, from a decavanadate stock solution of 5 or 50 mM. Kd values
were obtained from Scatchard plots of the fractional fluorescence
change, as indicated in the text, and are the average of at least triplicate
experiments.
FIGURE 4: Dependence of the fluorescence of S1(AF,SH2) upon
AP5A (A) and decavanadate (B) concentration. IAF fluorescence
(excitation wavelength 490 nm; emission wavelength 517 nm) was
measured at 25 °C, in 20 mM Hepes (pH 7.0), 25 mM KCl and
2.5 mM MgCl2. Panel A: Titration with AP5A of the fluorescence
of S1(AF,SH2) in the absence (squares) or presence (circles) of 5
íM V10 (50 íM total vanadium added as decavanadate). Panel B:
Titration with decavanadate of the fluorescence of S1(AF,SH2) in
the absence (squares) or presence (circles) of 200 íM AP5A.
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dependent on the concentration of V10. The increase of the
time after addition of ATP needed for the onset of the
reassociation process in the presence of V10 correlated well
with the extent of inhibition of the S1 ATPase activity by
V10, thus indicating that is the time needed to attain a
sufficiently low ATP level in the solution to allow for the
reassociation process to occur. Remarkably, however, the
kinetics of the reassociation between S1 and actin is notably
slowed in the presence of V10 (inset of Figure 5C), suggesting
the formation of nonproductive complexes induced by V10.
The formation of the complex between actin and S1 can
also be monitored by fluorescence energy transfer (48, 51,
52). To this end, we have labeled S1 with IAF (as the
fluorescent donor) and F-actin with eosin iodoacetamide
(eosin-F-actin). V10 produced only a small decrease of
energy transfer between IAF-S1 and eosin-F-actin, from
20 to 15% in the absence and the presence of 5 íM V10 (50
íM total vanadium) after correction for the effect of V10 on
IAF-S1 fluorescence (results not shown). Using the overlap
integral value (J) between IAF-S1 and eosin-F-actin and
donor (fluorescein in IAF-S1) quantum yield (QD) which
we have determined for our labeled samples (J ) 5.52 
10-14 cm3 M-1 and QD ) 0.35 ( 0.05), we have obtained a
R0 value for this donor-acceptor pair of 3.9 ( 0.1 nm.
Applying eq 1 of Materials and Methods, we have obtained
a distance between donor (fluorescein) and acceptor (eosin)
located in S1 and F-actin of 4.9 ( 0.1 and 5.2 ( 0.1 nm in
the absence and in the presence of 5 íM V10 (50 íM total
vanadium), respectively. Our distance estimation between
donor and acceptor dyes in the F-actin/S1 complex agrees
well with the values reported by others (48, 51, 52), and the
results confirm that V10 does not significantly dissociate the
F-actin/S1 complex in the experimental conditions that
produced a large inhibition of the actin-stimulated S1-ATPase
activity.
DISCUSSION
The kinetic studies presented in this paper showed that
V10 inhibits the actin-stimulated ATPase activity of myosin
S1, with an IC50 in the micromolar range, that this inhibition
is noncompetitive either with actin or with ATP, and
suggested that it can be due to the interaction of V10 with
one inhibitory binding site per myosin S1 with a Ki value of
0.27 ( 0.05 íM at pH 7.0 in the conditions used for the
kinetic assays. This Ki value is in the range of Ki values
usually found for enzymes inhibited by V10 (53). The large
effect of KCl on the dissociation constant of V10 from S1
indicates that electrostatic interactions plays a major role in
V10 (a polyanion) binding to myosin. The presence of a
binding site for polyvalent anions in the head of myosin has
been well documented (14, 54-57), and it was proposed that
they could account for the inhibition of the actomyosin
ATPase activity by polyvalent anions (54). Although the
surface electrostatic charge contour of S1 reveals the presence
of a protein region positively charged from residues 627 to
646, containing five Lys (loop 2), which makes part of the
actin-binding interface (50), it is very unlikely that the V10
polyanion high-affinity binding site we are probing at the
present work is located at this protein region because V10
binding to S1 is not affected by actin.
In this paper, we have shown that S1 labeled at Cys-707
with IAEDANS or IAF monitor the presence of one V10
binding site per monomer, with a dissociation constant in
the submicromolar range in the absence of nucleotides (ADP
or ATP), Kd ) 0.16-0.26 íM at 25 mM KCl concentration.
These values of the dissociation constant of the V10âS1
complex are close to the values for the inhibition constant
Ki obtained from kinetic studies carried out with unlabeled
S1 under the same experimental conditions, showing that
FIGURE 5: Effect of decameric vanadate on the dissociation and
aggregation of the acto-S1 complex. (A) Light scattering of the
acto-S1 complex (solid line) upon sequential additions of 5 íM
V10 (50 íM total vanadium added as decavanadate) plus 0.25 mM
ATP. (B) Light scattering of the acto-S1 complex upon ATP (0.25
mM) addition in the absence (solid line) or presence of 50 íM
metavanadate (dash line). (C) Light scattering of the acto-S1
complex upon ATP (0.25 mM) addition in the absence (solid line)
or presence of 1 íM (dash line) and 5 íM (dot line) V10, i.e., 10
and 50 íM total vanadium added as decavanadate, respectively.
Light scattering intensity at 90° with respect to the incident light
was measured with monochromators set at 500 nm, and is given in
arbitrary units (a.u.). The line joining circles denotes the sum of
S1 (triangles) plus actin (squares) light scattering intensities, and
the large double-headed arrows is the expected decrease of light
scattering for a 100% ATP-induced dissociation of the actin-S1
complex. The recovery of the light scattering monitored acto-S1
complex reassociation in the absence, or presence of 1 and 5 íM
V10, i.e., 10 and 50 íM total vanadium added as decavanadate (inset
plot). The experiments were carried out at 25 °C in 20 mM Hepes
(pH 7.0), 25 mM KCl and 2.5 mM MgCl2 with 0.9 íM of S1 and
2 íM actin.
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labeling of S1 at Cys-707 produced only a minor distortion
of the V10 binding site. In contrast, titration of S1(AEDANS,
SH2) and of S1(AF, SH2) with metavanadate showed that
orthovanadate has a much weaker affinity for S1, i.e., a Kd
> 50 íM, and consistently orthovanadate was found to be
only a weak competitor of decameric vanadate for binding
to this site. It is also shown that binding of V10 species can
be monitored as well from the quenching of the fluorescence
of S1 labeled with IAEDANS and IAF at the Cys-697 (SH2
group), located 1.8 nm from Cys-707 in the 3D-structure of
S1 (50), yielding values for the dissociation constant which
are similar to those obtained with S1 labeled with these dyes
at Cys-707 (SH1 group).
The extent of quenching produced by V10 on S1(AEDANS,
SH2) (30% at saturation) is much higher than the quenching
produced at saturation upon binding of many ligands to S1-
(AEDANS, SH2) (23). Also, the quenching produced by V10
on S1(SH1, AEDANS) (35-40% at saturation) is about 15-
20% higher than that produced on S1(SH1, AF) (20-25%
at saturation), although the labels were incorporated to the
same Cys-697 in S1 (see Materials and Methods). The
simplest way to account for this anomalous high quenching
is that V10 binds to a site very close to the AEDANS
covalently bound to S1, thereby producing a highly efficient
static quenching (which implies that both sites are separated
by at most 1.0 nm (58)) or acting as a good acceptor for the
fluorescence of AEDANS due to its absorption in the
emission wavelength range of AEDANS (calculated value
of the overlap integral J ) 0.223  10-15 cm3 M-1). In this
latter case, assuming that the excess quenching produced by
V10 on S1(SH1, AEDANS) with respect to that measured
for S1(SH1, AF) is due to energy transfer from IAEDANS
to V10, with the overlap integral indicated above and the
quantum yield obtained for AEDANS labeled S1 (QD ) 0.18
( 0.03, calculated as indicated in the Materials and Methods)
we obtain an R0 value of 1.39 ( 0.04 nm for this donor/
acceptor energy transfer pair. Using eq 1 (see Materials and
Methods), this will imply that the binding site for V10 is only
at 1.2-1.3 nm distance from AEDANS covalently bound to
Cys-697 in S1. The uncertainty caused by the assumption
of random orientation between AEDANS and V10 in this
distance estimation is low because (i) the measured fluores-
cence anisotropy of the donor (AEDANS bound to S1) is
0.15, which indicates a large rotational mobility of the donor
(calculated rotational cone semiangle ı ) 41.5° (see 38));
and (ii) the quasi-spherical geometry of the acceptor V10.
The flexible loop between Cys-707 and Cys-697 is thought
to act as an energy transduction element through which
intersite communication between ATP and actin binding sites
is transmitted. In fact, this region is known to change its
conformation along the ATPase kinetic pathway (21, 24, 25).
Therefore, conformational changes leading to transient
intermediate states during the catalytic cycle could alter the
affinity of myosin S1 for V10. ADPâV1 and ADPâAlF4 have
been shown to shift S1 to a state close to the M**âADPâPi
intermediate state generated during myosin ATPase activity
(22, 59, 60). Noteworthy, the dissociation constant of S1 for
V10 increased approximately 2- and 3-fold in the presence
of ADPâV1 and ADPâAlF4, respectively, suggesting that V10
has 2-3-fold lower affinity for the conformational state M**â
ADPâPi than for S1 conformational state in absence of
nucleotide. Different affinities for V10 of different confor-
mational states of myosin S1 should be expected to produce
an altered distribution of conformational states during steady-
state S1 catalytic activity in the presence of V10. In the
present work, it is demonstrated that V10 induced a small
change in the light scattering of the actin-S1 complex and
a decrease of the fluorescence energy transfer between IAF-
S1, with the donor dye covalently attached to Cys-707 of
myosin, and eosin-F-actin, with the acceptor dye covalently
attached to Cys-374 of actin. The decrease of fluorescence
energy transfer produced by V10 in the IAF-S1/eosin-F-
actin complex can be accounted for an increase of 3.0 (
1.2 Å of the distance between donor and acceptor dyes or a
change in the relative orientation between donor and acceptor
of about 25°. Such a change in distance falls within the range
of conformational-induced changes in distance between one
dye covalently bound to selected Cys or Lys amino acids in
the myosin S1 and a second dye attached to F-actin (48,
52), and also is in good agreement with the reported dynamic
structural fluctuation range of the myosin S1 between Cys-
707 and Cys-697 (61, 62).
In presence of saturating concentrations of AP5A the
association constant for V10 binding to S1 is approximately
36-fold lower than in absence of AP5A. Furthermore, at
saturation V10 also decreased almost 4-fold the association
constant for AP5A binding to S1. Therefore, V10 and AP5A
compete for binding to S1, suggesting that their binding sites
partially overlap or that they are very close in the 3D protein
structure. Computer molecular docking of AP5A to S1 has
shown that this ç-phosphate modified nucleotide analogue
binds to S1, extending from the nucleotide binding site
through the phosphate tube leading to the 50-K cleft (16,
49), but through a prior opening of the phosphate tube. This
tube structure that connects the nucleotide crevice of the
catalytic center and the back door in the 50-K cleft switches
between open and closed states during the catalytic cycle
(16, 49). Release of myosin from actin is caused by opening
the cleft between the lower and upper domains of the 50-
kDa segment when the ç-phosphate from ATP binds in the
active site pocket (50). The ç-phosphate of ATP lies adjacent
to Ser-180 and Ser-243, two residues known to be photo-
modified by vanadate upon UV irradiation (15). Ser-180 is
located on the 178-185 sequence which forms the consensus
ATP binding site of myosin and is homologous to the
polyphosphate binding site of a number of nucleotide binding
enzymes (63). Recently, Pezza et al. (64) have shown that
the Walker A motif of ABC ATPases is a highly adapted
anion-binding domain that can bind V10 with a dissociation
constant in the micromolar range and produce noncompetitive
inhibition. According to these authors, once the complex
decavanadate-ADP-Mg-protein is established, the ATP/
ADP exchange can be blocked, resulting in noncompetitive
inhibition with respect to ATP. In the present work, the
putative binding of V10 to the P-loop in S1 3D structure can
account for the results reported, briefly: (i) noncompetitive
inhibition with actin and ATP of the actin-stimulated S1-
ATPase activity and slower reassociation between S1 and
actin after ATP hydrolysis; (ii) large alteration of the
fluorescence of AEDANS and AF covalently bound to Cys-
707 and Cys-697 located near the P-loop in the 3D structure
of S1; (iii) competition with AP5A for binding to S1; and
(iv) a conformational shift of S1, as this P-loop orientation
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changes during the conformational changes taking place in
the catalytic cycle of ATP hydrolysis (49).
In summary, the results are consistent with binding of V10
to the Walker A motif of ABC ATPases, which in S1
corresponds to conserved regions of the P-loop that form
part of the phosphate tube. This V10 high-affinity binding
site produces noncompetitive inhibition of the actin-
stimulated S1-ATPase activity, without causing dissociation
of the acto-S1 complex. Moreover, the affinity of S1 for
V10 is modulated by the conformational changes that takes
place in S1 during the catalytic cycle, as indicated by the
2-3-fold increase of the dissociation constant produced in
the presence of ADPâV1 and ADPâAlF4, which induce a
conformational state close to the M**âADPâPi intermediate
state generated during myosin ATPase activity. Therefore,
the V10 species can be a useful tool to gain a deeper
knowledge of the “back door” modulation of the actin-
stimulated myosin ATPase activity and its relevance to
actomyosin interactions.
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